Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first in human modular, open-label, phase I/IIa study to evaluate the safety, tolerability, pharmacokinetics and anti-tumour activity of the specific dUTPase inhibitor CV6-168 in combination with anti­cancer treatments in patients with advanced malignancies

Next Previous
Trial Profile

A first in human modular, open-label, phase I/IIa study to evaluate the safety, tolerability, pharmacokinetics and anti-tumour activity of the specific dUTPase inhibitor CV6-168 in combination with anti­cancer treatments in patients with advanced malignancies

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CV6-168 (Primary) ; Fluorouracil; Folinic acid
  • Indications Breast cancer; Colon cancer; Colorectal cancer; Gastric cancer; Lung cancer; Malignant melanoma; Ovarian cancer; Pancreatic cancer
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors CV6 Therapeutics

Most Recent Events

  • 15 Aug 2024 According to CV6 Therapeutics media release, the Company announced the successful dosing of the second patient in its Phase 1a study evaluating CV6-168 + infusional 5-fluorouracil (5-FU) in cancer patients.
  • 29 May 2024 Trial design discussed in an abstract published at 60th Annual Meeting of the American Society of Clinical Oncology
  • 19 Apr 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top